Literature DB >> 24048123

Innate and adaptive immune cells in the tumor microenvironment.

Thomas F Gajewski1, Hans Schreiber, Yang-Xin Fu.   

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

Entities:  

Mesh:

Year:  2013        PMID: 24048123      PMCID: PMC4118725          DOI: 10.1038/ni.2703

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  147 in total

1.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Authors:  Masahisa Jinushi; F Stephen Hodi; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

2.  Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.

Authors:  Roberta Mortarini; Alessia Scarito; Daisuke Nonaka; Marina Zanon; Ilaria Bersani; Elisabetta Montaldi; Elisabetta Pennacchioli; Roberto Patuzzo; Mario Santinami; Andrea Anichini
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

3.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

4.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 6.  GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

Authors:  Vincent G Brichard; Diane Lejeune
Journal:  Vaccine       Date:  2007-09-27       Impact factor: 3.641

7.  Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.

Authors:  Seunghee Kim-Schulze; Hong Sung Kim; Qing Fan; Dae Won Kim; Howard L Kaufman
Journal:  Mol Ther       Date:  2008-11-25       Impact factor: 11.454

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  1338 in total

Review 1.  Organ-on-a-Chip for Cancer and Immune Organs Modeling.

Authors:  Wujin Sun; Zhimin Luo; Junmin Lee; Han-Jun Kim; KangJu Lee; Peyton Tebon; Yudi Feng; Mehmet R Dokmeci; Shiladitya Sengupta; Ali Khademhosseini
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

2.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 3.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

4.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

5.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

6.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

7.  The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.

Authors:  Maximilian Linxweiler; Fengshen Kuo; Nora Katabi; Mark Lee; Zaineb Nadeem; Martin G Dalin; Vladimir Makarov; Diego Chowell; Snjezana Dogan; Ian Ganly; A Ari Hakimi; Richard J Wong; Nadeem Riaz; Alan L Ho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

8.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Emanuelle M Rizk; Margaret Bogardus; Camille L Gérard; Luke W Barker; Yichun Fu; Camden L Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J Lee; John J Krolewski; Carl Morrison; Basil A Horst; Yvonne M Saenger
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

Review 9.  Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Authors:  Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 10.  Inflammation-on-a-Chip: Probing the Immune System Ex Vivo.

Authors:  Daniel Irimia; Xiao Wang
Journal:  Trends Biotechnol       Date:  2018-05-01       Impact factor: 19.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.